Cambium Bio Ltd risk profile
69 Stretched several inputs deteriorating together
Measured 21 October 2026 from CMB's filed statements. Recomputed nightly.
69 (Stretched), driven by Competitive position at 80, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 54 | Elevated | Stable | Drawdown from the 52-week high — 25.0% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 47 | Elevated | Stable | Interest cover — -7.32x |
| Competitive position | 80 | Acute | Stable | Operating-margin gap against peers — -255,026.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.